Lung Cancer最新文献

{"title":"Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer","authors":"Stephanie P.L. Saw ,&nbsp;Wen-Zhao Zhong ,&nbsp;Rui Fu ,&nbsp;Molly S.C. Li ,&nbsp;Yasushi Goto ,&nbsp;Stephen B. Fox ,&nbsp;Yasushi Yatabe ,&nbsp;Boon-Hean Ong ,&nbsp;Calvin S.H. Ng ,&nbsp;David D.W. Lee ,&nbsp;Pham Cam Phuong ,&nbsp;In Kyu Park ,&nbsp;James C.H. Yang ,&nbsp;Masahiro Tsuboi ,&nbsp;Lye Mun Tho ,&nbsp;Thomas John ,&nbsp;Hsao-Hsun Hsu ,&nbsp;Daniel S.W. Tan ,&nbsp;Tony S.K. Mok ,&nbsp;Thanyanan Reungwetwattana ,&nbsp;Navneet Singh","doi":"10.1016/j.lungcan.2024.108076","DOIUrl":"10.1016/j.lungcan.2024.108076","url":null,"abstract":"<div><div>The <em>peri</em>-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions. An interdisciplinary group of 19 experts comprising medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists and pathologists from Singapore, Hong Kong, Mainland China, Korea, Japan, Taiwan, India, Malaysia, Thailand, Vietnam and Australia met to discuss emerging data, identify existing gaps in clinical care and develop a multidisciplinary, multinational expert consensus statement on the <em>peri</em>-operative management of NSCLC tailored to the Asia-Pacific region.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108076"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group","authors":"L. Decoster ,&nbsp;D.R. Camidge ,&nbsp;J.A. Fletcher ,&nbsp;A. Addeo ,&nbsp;A. Greystoke ,&nbsp;K. Kantilal ,&nbsp;L.Bigay Game ,&nbsp;R. Kanesvaran ,&nbsp;F. Gomes","doi":"10.1016/j.lungcan.2025.108087","DOIUrl":"10.1016/j.lungcan.2025.108087","url":null,"abstract":"<div><div>Lung cancer is mostly a disease of aging with approximately half of newly diagnosed patients being 70 years or older. Treatment decisions in this population pose unique challenges because of their heterogeneity with regards to daily functioning, cognition, organ function, comorbidities and polypharmacy, their underrepresentation in clinical trials and the impact of treatment on patient-centered outcomes, particularly in frail patients.</div><div>The advent of targeted therapies and immunotherapy has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Molecular profiling has allowed for the identification of actionable genomic alterations and targeted therapies have become standard of care for oncogene-driven NSCLC, significantly improving prognosis and quality of life. However, the data on the efficacy and tolerability of these treatments in older patients remain sparse.</div><div>This review, conducted by the International Society of Geriatric Oncology (SIOG) NSCLC task force, examines the available literature on the use of targeted therapies in patients aged 70 years or older with oncogene-driven NSCLC. The task force’s expert recommendations aim to guide treatment decisions for older patients with oncogene driven NSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108087"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study","authors":"Leilei Wu ,&nbsp;Jia-Yuan Tian ,&nbsp;Ming-Jun Li ,&nbsp;Feng Jiang ,&nbsp;Li-Hong Qiu ,&nbsp;Wan-Jun Yu ,&nbsp;Xiao-Lu Chen ,&nbsp;Rang-Rang Wang ,&nbsp;Kun Li ,&nbsp;Guo-Wei Ma ,&nbsp;Jian Zeng ,&nbsp;Dong Xie","doi":"10.1016/j.lungcan.2025.108085","DOIUrl":"10.1016/j.lungcan.2025.108085","url":null,"abstract":"<div><h3>Objectives</h3><div>The 9th edition of the tumor-node-metastasis (TNM) staging system for lung cancer was proposed at the 2023 World Conference on Lung Cancer in Singapore. This study aimed to externally validate and compare the latest staging of small-cell lung cancer (SCLC).</div></div><div><h3>Methods</h3><div>Four hundred and eight patients with limited-stage SCLC were collected after lung resection from four centers. Survival curves by TNM stages were drawn using the Kaplan-Meier method and further compared by the Log-rank test. The Cox regression, receiver operating characteristics curves, area under the curve (AUC), Akaike information criterion (AIC), Bayesian information criterion (BIC), and Concordance index (C-index) were used in this study.</div></div><div><h3>Results</h3><div>In comparing IA <em>vs.</em> IIB, IIA <em>vs.</em> IIB, IIA <em>vs.</em> IIIA, IIA <em>vs.</em> IIIB, and IIIA <em>vs.</em> IIIB, the 9th edition had a better distinguishing ability than the eighth staging system (all <em>p</em> &lt; 0.05). Besides, the 9th edition TNM staging had better predictive power and accuracy for the overall survival (OS) of SCLC patients over the 8th edition (AUC of 3-year OS: 0.680 <em>vs.</em> o.668; AIC: 4425.25 <em>vs.</em> 4444.52; BIC: 4493.44 <em>vs.</em> 4512.71; C-index: 0.637 [0.04] <em>vs.</em> 0.629 [0.039], <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Our external validation demonstrates that the ninth edition of pathological TNM staging for limited-stage SCLC is reasonable and valid based on a multicenter study. The ninth edition has better prognostic accuracy than the eighth edition.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108085"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of single nucleotide polymorphisms rs7459185 of the HSPβ1 gene and the risk of hematological toxicity in lung cancer","authors":"Óscar Muñoz Muñoz ,&nbsp;Blas David Delgado León ,&nbsp;Elías Gomis Sellés ,&nbsp;María Valle Enguix-Riego ,&nbsp;Jon Cacicedo Fernández de Bobadilla ,&nbsp;Juan Manuel Praena-Fernández ,&nbsp;Eleonor Rivin del Campo ,&nbsp;José Luis López Guerra","doi":"10.1016/j.lungcan.2025.108103","DOIUrl":"10.1016/j.lungcan.2025.108103","url":null,"abstract":"<div><h3>Purpose</h3><div>Hematological toxicities (HTs) in lung cancer (LCa) may compromise the delivery of Radio-Chemotherapy (RTCT), and consequently affect the control of the disease. The aim of this study is to evaluate the association of Single nucleotide polymorphisms (SNPs) with HT.</div></div><div><h3>Material/Methods</h3><div>In this prospective multicentre study, 264 patients with primary LCa treated with RTCT between 2012 and 2018 were included. Genotyping analysis was performed on DNA isolated from peripheral blood samples by real-time polymerase chain reaction (PCR) using TaqMan. HTs were scored using the Common Toxicity Criteria (CTCAE) version 5.0.</div></div><div><h3>Results</h3><div>An increased risk of HT ≥ grade 2 was observed in patients with the GG genotype of the SNP rs7459185 (HSPβ1) with a hazard ratio (HR) of 1.462 (95 %CI 1.054–2.029, p = 0.007). Similarly, those patients had an increased risk of overall HT ≥ grade 3 with a HR of 1.531 (95 %CI 1.016–2.30, p = 0.007). The patients with the GG genotype experienced an acute lymphopenia ≥ Grade 3 (HR 1.590 [95 %CI 1.004–2.517; p 0.045]) and acute anemia ≥ Grade 2 (HR 1.886 [95 %CI 1.060–3.356; p 0.032]), compared to the GC/CC genotypes.</div></div><div><h3>Conclusion</h3><div>Our findings show a relationship between the functional GG genotypic of the SNP rs7459185 (HSPβ1) and heightened risk the development of HT, including anemia and lymphopenia in patients with LCa. This genetic variant could be utilized as a predictive marker to tailor treatment intensity, contributing to the advancement of individualized therapeutic approaches.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108103"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database","authors":"Satoshi Ikeda ,&nbsp;Takashi Ogura ,&nbsp;Etsuo Miyaoka ,&nbsp;Ikuo Sekine ,&nbsp;Takehito Shukuya ,&nbsp;Koichi Takayama ,&nbsp;Akira Inoue ,&nbsp;Isamu Okamoto ,&nbsp;Masahiro Seike ,&nbsp;Kazuhisa Takahashi ,&nbsp;Nobuyuki Yamamoto ,&nbsp;Masaya Yotsukura ,&nbsp;Shun-ichi Watanabe ,&nbsp;Yasushi Shintani","doi":"10.1016/j.lungcan.2025.108102","DOIUrl":"10.1016/j.lungcan.2025.108102","url":null,"abstract":"<div><h3>Introduction</h3><div>Data on chemotherapy for elderly, poor performance status (PS) non-small cell lung cancer (NSCLC) are clinically important but insufficient due to their exclusion from most interventional studies. This study aims to explore actual treatment status and prognosis, as well as factors predicting patients who may benefit from chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>Advanced NSCLC patients aged ≥75 years with PS 2–3 and no/unknown driver mutations were included. In each of PS2 and PS3 cohorts, we compared the overall survival (OS) of the chemotherapy and Best Supportive Care (BSC) group after adjusting by inverse probability weighting (IPW) method, and analyzed prognostic factors using the COX proportional hazards model. We defined the patients with body weight loss ≥5 % within 6 months as cancer cachexia in this study.</div></div><div><h3>Results</h3><div>This study included 282 patients (Chemotherapy;107, BSC;175) in PS2 cohort and 230 patients (Chemotherapy;39, BSC;191) in PS3 cohort. In both PS2 and PS3 cohorts, IPW-adjusted OS was significantly longer in the chemotherapy group than in the BSC group (HR 0.42 [95 % CI 0.32–0.55] and 0.56 [95 % CI 0.41–0.75], p &lt; 0.001 and 0.003, respectively). Multivariate analysis showed that cancer cachexia and stage IV were significantly associated with OS in PS2 cohort. For patients with cancer cachexia in PS3 cohort, chemotherapy did not prolong OS (HR 0.81 [95 % CI 0.45–1.45], p = 0.530).</div></div><div><h3>Conclusion</h3><div>Chemotherapy might provide a survival benefit even for elderly, poor PS NSCLC patients. In vulnerable PS 3 patients, cancer cachexia may be useful in predicting patients who may benefit from chemotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108102"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist","authors":"Paul Hofman ,&nbsp;Iordanis Ourailidis ,&nbsp;Eva Romanovsky ,&nbsp;Marius Ilié ,&nbsp;Jan Budczies ,&nbsp;Albrecht Stenzinger","doi":"10.1016/j.lungcan.2025.108110","DOIUrl":"10.1016/j.lungcan.2025.108110","url":null,"abstract":"<div><div>The rapid development of artificial intelligence (AI) based tools in pathology laboratories has brought forward unlimited opportunities for pathologists. Promising AI applications used for accomplishing diagnostic, prognostic and predictive tasks are being developed at a high pace. This is notably true in thoracic oncology, given the significant and rapid therapeutic progress made recently for lung cancer patients. Advances have been based on drugs targeting molecular alterations, immunotherapies, and, more recently antibody-drug conjugates which are soon to be introduced. For over a decade, many proof-of-concept studies have explored the use of AI algorithms in thoracic oncology to improve lung cancer patient care. However, despite the enthusiasm in this domain, the set-up and use of AI algorithms in daily practice of thoracic pathologists has not been operative until now, due to several constraints. The purpose of this review is to describe the potential but also the current barriers of AI applications in routine thoracic pathology for non-small cell lung cancer patient care and to suggest practical solutions for rapid future implementation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108110"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating lung cancer risk factors in adults with interstitial lung disease","authors":"Jane Dobkin ,&nbsp;B. Payne Stanifer ,&nbsp;Mary Salvatore ,&nbsp;Christina M. Eckhardt","doi":"10.1016/j.lungcan.2025.108416","DOIUrl":"10.1016/j.lungcan.2025.108416","url":null,"abstract":"<div><h3>Background</h3><div>Adults with interstitial lung disease (ILD) have a higher risk of developing lung cancer compared to the general population. We aimed to identify ILD-specific risk factors that can be used to improve lung cancer detection in this high-risk population.</div></div><div><h3>Methods</h3><div>Adults ≥21 years who received at least two chest CT scans at an academic medical center between 2005 and 2020 and were found to have ILD were studied retrospectively. Lung cancer diagnoses were adjudicated based on pathology reports from lung biopsies. Logistic regression was used to evaluate associations of clinical variables with comorbid lung cancer.</div></div><div><h3>Results</h3><div>Among 1,366 adults with ILD, the mean age was 67.2 ± 12.4 years and 639 (46.8 %) were men. In total, 227 adults (16.6 %) had a lung nodule on CT imaging, of whom 55 (24.3 %) were diagnosed with lung cancer. Radiographic usual interstitial pneumonia (UIP) (OR 3.00, 95 % CI 1.43–6.33) was independently associated with increased odds of lung cancer. Risk factors including age, sex, smoking status, pack-years, use of immunosuppression, and radiographic fibrosis pattern collectively demonstrated high discriminative accuracy in predicting comorbid lung cancer, even among adults who would not have qualified for lung cancer screening based on current guidelines (AUC 0.80, 95 % CI 0.72–0.88).</div></div><div><h3>Conclusions</h3><div>In a large study of adults with ILD, radiographic UIP was independently associated with comorbid lung cancer even after adjusting for established risk factors. Our results suggest radiographic UIP is an independent lung cancer risk factor and support the development of targeted lung cancer screening guidelines in adults with UIP.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108416"},"PeriodicalIF":4.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases","authors":"Zhiyuan Yao ,&nbsp;Tong Qiu ,&nbsp;Changlei Li ,&nbsp;Weimao Kong ,&nbsp;Guangqi Li ,&nbsp;Peng Song ,&nbsp;Guohua Wang ,&nbsp;Wenjie Jiao","doi":"10.1016/j.lungcan.2025.108414","DOIUrl":"10.1016/j.lungcan.2025.108414","url":null,"abstract":"<div><h3>Background</h3><div>Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations.</div></div><div><h3>Method</h3><div>Paraffin-embedded specimens of primary PACC tissues pathologically confirmed at the Affiliated Hospital of Qingdao University within the past decade were collected. We comprehensively evaluated the diversity of molecular alterations in PACC using immunohistochemistry (IHC) staining, fluorescence <em>in-situ</em> hybridization (FISH), and next-generation sequencing (NGS). Furthermore, the potential correlations between MYB rearrangement status and clinicopathological features were thoroughly analyzed.</div></div><div><h3>Result</h3><div>Twenty-one specimens of primary PACC were collected, including eighteen of the typical type and three of the solid-basaloid type. Fifteen (71.4 %) specimens exhibited positive MYB staining and MYB rearrangements. Notably, neither clinicopathological parameters nor MYB rearrangement predicted patients’ overall survival (OS). However, MYB non-rearrangement was associated with a significantly higher rate of lymph node metastasis (75 % vs. 8.3 %, P = 0.027).</div></div><div><h3>Conclusion</h3><div>Investigating the heterogeneity and multimolecular characteristics of PACC based on different pathological types emerges as a potentially innovative strategy to pinpoint suitable candidates for targeted therapies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108414"},"PeriodicalIF":4.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143163967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer","authors":"Paul Hofman ,&nbsp;Petros Christopoulos ,&nbsp;Nicky D’Haene ,&nbsp;John Gosney ,&nbsp;Nicola Normanno ,&nbsp;Ed Schuuring ,&nbsp;Ming-Sound Tsao ,&nbsp;Christine Quinn ,&nbsp;Jayne Russell ,&nbsp;Katherine E Keating ,&nbsp;Fernando López-Ríos","doi":"10.1016/j.lungcan.2025.108107","DOIUrl":"10.1016/j.lungcan.2025.108107","url":null,"abstract":"<div><div>The implementation of biomarker testing for targeted therapies and immune checkpoint inhibitors is a cornerstone in the management of metastatic and locally advanced non-small cell lung cancer (NSCLC), playing a pivotal role in guiding treatment decisions and patient care. The emergence of precision medicine in the realm of operable NSCLC has been marked by the recent approvals of osimertinib, atezolizumab, nivolumab, pembrolizumab and alectinib for early-stage disease, signifying a shift towards more tailored therapeutic strategies. Concurrently, the landscape of this disease is rapidly evolving, with several further pending approvals and numerous clinical trials in progress.</div><div>To harness the benefits of these innovative neo-adjuvant and adjuvant therapies, the integration of predictive biomarker testing into standard clinical protocols is imperative for patients with operable NSCLC. A multidisciplinary international consortium has identified three primary obstacles impeding the effective testing of patients with operable NSCLC. These challenges encompass the limited number of test requests by physicians, the inadequacy of tissue samples for comprehensive testing, and the prevalence of cost-reduction measures leading to suboptimal testing practices.</div><div>This review delineates the aforementioned challenges and proposed solutions, and strategic recommendations aimed at enhancing the testing process. By addressing these issues, we strive to optimize patient outcomes in operable NSCLC, ensuring that individuals receive the most appropriate and effective care based on their unique disease profile.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108107"},"PeriodicalIF":4.5,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143163966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial","authors":"Ki Hyeong Lee ,&nbsp;Jong-Seok Lee ,&nbsp;Shunichi Sugawara ,&nbsp;Jin Hyoung Kang ,&nbsp;Hye Ryun Kim ,&nbsp;Naoki Inui ,&nbsp;Toyoaki Hida ,&nbsp;Tatsuya Yoshida ,&nbsp;Hiroshi Tanaka ,&nbsp;Cheng-Ta Yang ,&nbsp;Takako Inoue ,&nbsp;Makoto Nishio ,&nbsp;Yuichiro Ohe ,&nbsp;Tomohide Tamura ,&nbsp;Nobuyuki Yamamoto ,&nbsp;Chong-Jen Yu ,&nbsp;Hiroaki Akamatsu ,&nbsp;Shigeru Takahashi ,&nbsp;Kazuhiko Nakagawa","doi":"10.1016/j.lungcan.2025.108109","DOIUrl":"10.1016/j.lungcan.2025.108109","url":null,"abstract":"<div><h3>Objectives</h3><div>In the randomized phase III TASUKI-52 trial, nivolumab with carboplatin, paclitaxel, and bevacizumab significantly prolonged the progression-free survival (PFS) of treatment-naive patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). Here, we report the long-term outcomes of patients treated with nivolumab plus carboplatin, paclitaxel, and bevacizumab with 3 years of follow-up.</div></div><div><h3>Methods</h3><div>Patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing <em>EGFR</em>, <em>ALK</em>, or <em>ROS1</em> mutations were randomized (1:1) to receive either nivolumab or placebo, in addition to carboplatin, paclitaxel, and bevacizumab, every 3 weeks. Treatment was continued for a maximum of six cycles. The endpoints included PFS, overall survival (OS), and safety. Exploratory analyses included efficacy and safety in subgroups.</div></div><div><h3>Results</h3><div>A total of 550 patients were randomized to the nivolumab arm (n = 275) and placebo arm (n = 275). At the minimum follow-up of 36.1 months, PFS was consistently longer in the nivolumab arm than in the placebo arm (median, 10.6 vs. 8.2 months; hazard ratio [HR], 0.59; 95 % confidence interval [CI], 0.47–0.73; <em>P &lt;</em> 0.0001), with PFS rates of 20.2 % vs. 4.9 %. The median OS was 31.6 months (95 % CI, 26.8–36.5) in the nivolumab arm and 24.7 months (95 % CI, 21.1–28.0) in the placebo arm (HR, 0.71; 95 % CI, 0.57–0.88), with OS rates of 44.2 % and 32.3 %, respectively. Of note, PFS and OS favored the nivolumab arm across patients with different PD-L1 expression levels, and regardless of baseline brain metastasis status. Grade 3–4 treatment-related adverse events occurred in 76.2 % and 74.9 % of the patients in the nivolumab and placebo arms, respectively, while no new safety concerns were identified.</div></div><div><h3>Conclusion</h3><div>Nivolumab, in addition to carboplatin, paclitaxel, and bevacizumab, remained to demonstrate significantly longer PFS and long-term OS benefit compared with placebo in the first-line treatment of patients with nonsquamous NSCLC. The extended follow-up identified no new safety signals.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108109"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}